Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Elutia Inc., 3 years.
Elutia Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 22, 2026 | Acumen Pharmaceuticals Inc. | Open-market sale | −1,687 | $1.86 | $3,138 |
| Jan 21, 2026 | Acumen Pharmaceuticals Inc. | Open-market sale | −2,473 | $1.81 | $4,476 |
| Jan 16, 2026 | Acumen Pharmaceuticals Inc. | Grant or award | +99,133 | — | — |
| Jan 8, 2026 | Acumen Pharmaceuticals Inc. | Open-market sale | −6,888 | $1.82 | $12,536 |
| Jan 7, 2026 | Acumen Pharmaceuticals Inc. | Open-market sale | −4,105 | $2.00 | $8,210 |
| Jan 7, 2026 | Acumen Pharmaceuticals Inc. | Open-market sale | −1,700 | $1.99 | $3,383 |
| Jan 6, 2026 | Acumen Pharmaceuticals Inc. | Open-market sale | −5,100 | $1.97 | $10,047 |
| Jan 5, 2026 | Acumen Pharmaceuticals Inc. | Open-market sale | −4,000 | $1.96 | $7,840 |
| Jan 23, 2025 | Acumen Pharmaceuticals Inc. | Open-market sale | −28,902 | $1.72 | $49,711 |
| Jan 21, 2025 | Acumen Pharmaceuticals Inc. | Open-market sale | −4,364 | $1.60 | $6,982 |
| Jan 6, 2025 | Acumen Pharmaceuticals Inc. | Grant or award | +66,800 | — | — |
| Jan 3, 2025 | Acumen Pharmaceuticals Inc. | Open-market sale | −13,235 | $1.84 | $24,352 |
| Jan 18, 2024 | Acumen Pharmaceuticals Inc. | Open-market sale | −4,242 | $3.71 | $15,738 |
| Jan 2, 2024 | Acumen Pharmaceuticals Inc. | Grant or award | +106,000 | — | — |
Questions about Matt Zuga
What boards is Matt Zuga on?
Matt Zuga sits on the board of Elutia Inc.
How long has Matt Zuga served on boards?
Our records show at least 3 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.